Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis.

Molecular neurobiology - 1 Sept 2021

Carrasco-Campos María Isabel, Pérez-Ramírez Cristina, Macías-Cortés Elena, Puerta-García Elena, Sánchez-Pozo Antonio, Arnal-García Carmen, Barrero-Hernández Francisco Javier, Calleja-Hernández Miguel Ángel, Jiménez-Morales Alberto, Cañadas-Garre Marisa

Abstract excerpt

First-line therapy with interferon beta (IFN-β), involved in gene expression modulation in immune response, is widely used for multiple sclerosis. However, 30-50% of patients do not respond optimally. Variants in CBLB, CTSS, GRIA3, OAS1 and TNFRSF10A genes have been proposed to contribute to the variation in the individual response. The purpose of this study was to evaluate the influence of gene polymorphisms on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2',5'-Oligoadenylate Synthetase
Share to Cathepsins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-beta

Share to Multiple Sclerosis

Share to Pharmacogenetics

Share to Proto-Oncogene Proteins c-cbl

Share to Receptors, AMPA

Share to Receptors, TNF-Related Apoptosis-Inducing Ligand

Source

Identifiers

PMID: 34169444
DOI: 10.1007/s12035-021-02454-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic Predictors of Response to Interferon Beta Therapy in Multiple Sclerosis.PMID 34169444Read ↗

Pharmacogenetic study of long-term response to interferon-β treatment in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals drug-response markers.Semantic proximity Read ↗

Association study of promoter polymorphisms of interferon alpha and beta receptor subunit 1 (IFNAR1) gene and therapeutic response to interferon-beta in patients with multiple sclerosis.Semantic proximity Read ↗

Pharmacogenomics of response to interferon-beta and glatiramer acetate in Multiple Sclerosis: A multi-centric study.Semantic proximity Read ↗

Allelic combinations of immune-response genes as possible composite markers of IFN-β efficacy in multiple sclerosis patients.Semantic proximity Read ↗

Single-nucleotide polymorphisms in response to interferon-beta therapy in multiple sclerosis.Semantic proximity Read ↗

Pharmacogenetics of multiple sclerosisSemantic proximity Read ↗

Altered Immune Phenotypes and HLA-DQB1 Gene Variation in Multiple Sclerosis Patients Failing Interferon β Treatment.Semantic proximity Read ↗

IFN-beta pharmacogenomics in multiple sclerosis.Semantic proximity Read ↗

Immune response genes receptors expression and polymorphisms in relation to multiple sclerosis susceptibility and response to INF-β therapy.Semantic proximity Read ↗

Comparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.Semantic proximity Read ↗

TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.